Kirby McInerney LLP is investigating potential claims against the Board of Directors of NuPathe Inc. (“NuPathe” or the “Company”) (NASDAQ: PATH) concerning the proposed acquisition of the Company by Endo Health Solutions Inc. (“Endo”) (NASDAQ: ENDP). Under the terms of the definitive merger agreement, NuPathe stockholders will receive $2.85 in cash for each share of NuPathe owned, valuing the transaction at approximately $105 million.
The investigation concerns whether the NuPathe Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the $2.85 per share proposed consideration adequately values NuPathe’s common stock.
If you are a NuPathe stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at email@example.com, by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.
Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.